BUENA, N.J., Oct. 9, 2014 /PRNewswire/ -- IGI
Laboratories, Inc. (NYSE MKT: IG), a New
Jersey-based specialty generic pharmaceutical company, today
announced that it has appointed Steven
Koehler to its Board of Directors. Mr. Koehler will serve as
the new Chairman of the Company's Audit Committee.
Jason Grenfell-Gardner, President
and CEO of the Company, commented, "We are very pleased Steven has
agreed to join our Board of Directors. I believe his financial
expertise, and executive experience at global pharmaceutical
companies will be a tremendous asset to IGI, our audit committee
and our Board." Mr. Grenfell-Gardner continued, "We look
forward to working with Steven, as we continue on our mission to be
a leader in the specialty generic prescription drug markets."
Mr. Koehler retired from Merck & Co in September of 2011,
where he served as Vice President, Schering-Plough Controller and
Special Projects. Prior to this role, Mr. Koehler served as the
Vice President, Corporate Controller of Schering-Plough
Corporation, where he also served as Chief Accounting Officer and
was directly responsible for accounting and internal control
matters worldwide. Before joining Schering-Plough Corporation,
he served in several capacities at The Medicines Company, including
SVP and Chief Financial Officer. Prior to The Medicines
Company, Mr. Koehler served in various executive and senior level
positions at Vion Pharmaceuticals, Inc., Knoll Pharmaceuticals,
Inc., a wholly owned subsidiary of BASF Corporation, Boots
Pharmaceuticals, Inc. and American Hospital Supply Corporation, and
then with Baxter International after a merger in 1985. Mr. Koehler
began his career at Arthur Andersen in Chicago, holds a B.A. from Duke University, and an MBA degree from the Kellogg
Graduate School of Management at Northwestern
University. He is also a Certified Public Accountant.
About IGI Laboratories, Inc.
IGI Laboratories is a
specialty generic drug development and manufacturing company. Our
mission is to be a leading player in the specialty generic
prescription drug market.
Forward-Looking Statements
This press release includes certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, plans, objectives, expectations and intentions, and
other statements contained in this press release that are not
historical facts and statements identified by words such as "plan,"
"believe," "continue", "should" or words of similar meaning.
Factors that could cause actual results to differ materially from
these expectations include, but are not limited to: our inability
to meet current or future regulatory requirements in connection
with existing or future ANDAs; our inability to achieve
profitability; our failure to obtain FDA approvals as anticipated;
our inability to execute and implement our business plan and
strategy; the potential lack of market acceptance of our products;
our inability to protect our intellectual property rights; changes
in global political, economic, business, competitive, market and
regulatory factors; and our inability to complete successfully
future product acquisitions. These statements are based on our
current beliefs or expectations and are inherently subject to
various risks and uncertainties, including those set forth under
the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
other periodic reports we file with the Securities and Exchange
Commission. IGI Laboratories, Inc. does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130827/MM70487LOGO
SOURCE IGI Laboratories, Inc.